Company Announcement no. 27/2008
To: OMX Nordic Exchange Copenhagen Hørsholm, Denmark, August 14, 2008
LifeCycle Pharma's Updated Financial Calendar 2008
LifeCycle Pharma A/S (OMX:LCP) issues today an updated financial calendar for
2008:
August 21, 2008: Interim Report for 2nd Quarter - for the period ending June
30, 2008.
November 27, 2008: Interim Report for 3rd Quarter - for the period ending
September 30, 2008.
Contact:
LifeCycle Pharma A/S
Hans Christian Teisen
Executive Vice President and CFO
+45 7033 3300
HCT@lcpharma.com
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the US market and a
diversified near- and medium-term pipeline, including four product candidates
in clinical trials and two in preclinical stages of development. LCP is listed
on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For
further information, please visit www.lcpharma.com.
